Heartbeam, Inc. · NASDAQ:BEAT
Heartbeam — Investor Presentation (September 2026)
39 slides from Heartbeam's investor presentation, September 2026
Slide 1: Total Heart Intelligence… Wherever You Are
Total Heart Intelligence… Wherever You Are ADVANCED CARDIAC INTELLIGENCE PLATFORM | 26 PATENTS | FDA CLEARED* INVESTOR PRESENTATION September 2026 *FDA cleared for arrhythmia assessment only. NASDAQ: BEAT
Slide 2: Disclaimer
Disclaimer This presentation contains forward-looking statements. All statements other than statements of historical fact contained in this presentation, including statements as to the Company's future results of operations and financial position, planned products and services, business strategy and
Slide 3: The Gap in Cardiac Detection
THE GAP IN CARDIAC DETECTION Heart attack detection requires 12-Lead ECG data, which is primarily available in clinical settings. Consumer and wearable ECG devices do not provide sufficient spatial orientation for ischemia detection. As a result, clinicians lack reliable data when symptoms occur out
Slide 4: Patient Delay is the Major Driver Behind the #1 Cause of Death
Patient Delay is the Major Driver Behind the #1 Cause of Death Treatment time in hospital is optimized. Patient delay happens before arrival. Optimized, in guidelines Patients Delay 3+ Hours Treatment Time is Optimized Before Taking Action Once the Patient Reaches the Hospital Uncertainty Delays Act
Slide 5: Consumer ECGs Have Limited Capabilities
Consumer ECGs Have Limited Capabilities & Traditional ECGs are Limited to Healthcare Facilities Consumer wearables like 12-Lead ECGs: Apple Watch use only a Gold standard that’s single-lead ECG trapped in the hospital Noisy signals Bulky equipment and wires Limited diagnostic capabilities Requires t
Slide 6: HeartBeam Brings a Clinical-Grade 12-Lead ECG Into the Home
HeartBeam Brings a Clinical-Grade 12-Lead ECG Into the Home Investor Presentation 2026 6
Slide 7: A Cardiac Intelligence Platform…Anywhere
BRINGING CARE BEYOND THE HOSPITAL A Cardiac Intelligence Platform…Anywhere. Powered by FDA-cleared ECG technology. HeartBeam is the first ever cable-free, synthesized, 12-Lead ECG platform for arrhythmia assessment, delivering clinical-grade insights in real time, wherever symptoms occur. Investor P
Slide 8: Click here to watch the demo video
Click here to watch the demo video Click here to watch the demo video Investor Presentation 2026 8 FDA cleared for arrhythmia assessment only. Heart attack detection and AI algorithm products not cleared by FDA and not available for sale in the United States or other geographies.
Slide 9: Powered by 26 Patents Worldwide and Our Proprietary TriCor 3D Signal Reconstruction
Powered by 26 Patents Worldwide and our Proprietary TriCor 3D Signal Reconstruction Capturing the Heart’s Signals Novel Form Factor Clinically Accurate in 3 Dimensions Conversion Patented method that collects heart Proprietary resistive network enables a Personalized algorithms convert signals signa
Slide 10: This Platform Addresses Tens of Millions of Patients
This Platform Addresses Tens of Millions of Patients Across Multiple Segments Investor Presentation 2026 10
Slide 11: 50M+ Patient, $40B Cardiac Platform Opportunity
50M+ Patient, $40B Cardiac Platform Opportunity Scaling from direct-pay launch to large areas of clinical need INITIAL MARKET ENTRY POINT 1.5M PATIENTS Concierge & Preventive Cardiology PATIENTS EXPANSION OPPORTUNITY 5M+ 20M+ 50M+ 3.5M STRUCTURED DIRECT-PAY HEALTHCARE High touch HEART ATTACK RISK Ad
Slide 12: One Platform. Multiple Form Factors.
CORE PLATFORM One platform. Multiple form TRICOR PATENTED 3D SIGNAL factors. COLLECTION TECHNOLOGY Shared cardiac intelligence. FORM FACTORS HEARTBEAM SYSTEM* 12-LEAD PATCH CONTINUOUS 1-LEAD → HEARTBEAM REMOTE UNIT CABLE-FREE 12-LEAD ECG 12-LEAD ON DEMAND PRIMARY APPLICATION FOR AT-HOME USE OUTSIDE
Slide 13: The HeartBeam System is FDA Cleared and Being Launched
The HeartBeam System is FDA Cleared and Being Launched Investor Presentation 2026 13
Slide 14: HeartBeam System Cleared and Ready For Launch
HeartBeam System Cleared and Ready For Launch FDA 510(k) clearances for arrhythmia detection: 12/2024: The HeartBeam System 12/2025: 12-Lead ECG synthesis ambulatory ECG system Strong IP: 26 Issued Patents Worldwide Robust Clinical Evidence: 14 Clinical Papers & Presentations Investor Presentation 2
Slide 15: Execution on a Focused US Commercialization Strategy
Execution on a Focused US Commercialization ➢ Commercially- ➢ Signed multiple commercial released product agreements Strategy • End-to-end 24/7 reader service, • Covers all 4 target markets: NYC, onboarding workflow, and customer Dallas, South Florida, Southern success all live California • 24/7 rea
Slide 16: Concierge and Preventive Cardiology: an Initial Market and a Sales Channel
Concierge and Preventive Cardiology: an Initial Market and a Sales Channel Patients are demanding it. Physicians want to offer it. PATIENTS PHYSICIANS Patients actively seek advanced technology Demand latest clinical Tech-forward early adopters innovations and technology Desire to differentiate thei
Slide 17: HeartBeam Product Offering: Annual Subscription to Patients
HeartBeam Product Offering: Annual Subscription to Patients Equipment Services Routine Recordings Symptomatic Cable-free 12L ECG synthesized through 3D ECG technology Unlimited Reads Credits for On-call (Automated arrhythmia cardiologist ECG assessment, est. end of 2026) interpretation in <30 min Ad
Slide 18: Heart Attack Detection: A Huge Untapped Market
Heart Attack Detection: A Huge Untapped Market Investor Presentation 2026 18
Slide 19: Every 40 Seconds, Someone in the U.S. Suffers from a Heart Attack
Every 40 Seconds, Someone in the U.S. Suffers from a Heart Attack HeartBeam has developed 3 form factors to address the unmet need, each with a unique approach HeartBeam System On-Demand HeartBeam Remote (Card) 12-Lead Patchi Uniti • Post-discharge monitoring • Extended monitoring with • Remote/rura
Slide 20: Heart Attack Detection: Accelerating Path to Indication Expansion
Heart Attack Detection: Accelerating Path to Indication Expansion Future indication expansion would unlock a large addressable market of millions of patients at risk ✓ Completed enrollment in less than 4 months, ahead of schedule ALIGN-ACS ✓ Enrolled 134 patients presenting with chest pain in the E.
Slide 21: HeartBeam Vision for Heart Attack Detection
HeartBeam Vision for Heart Attack Detection Physician augmented by deep learning algorithm with insights into STEMI and NSTEMI Patient With 24/7Cloud-Based Cardiologist AI Interpretation of ECG ECG Data Cardiologist reviews: Cardiologist • ECG reviews: • • ECG Baseline ECG Symptoms • • Baseline ECG
Slide 22: HeartBeam AI Uniquely Brings 12-Lead Personalized Insights to Patients at Home
HeartBeam AI Uniquely Brings 12-Lead Personalized Insights to Patients at Home 12-Lead ECG AI exists today, but only in clinical settings. HeartBeam enables longitudinal 12-Lead insights at home. 12-Lead ECG + AI Today HeartBeam’s CLINICALLY PROVEN ACROSS: Differentiation DRIVERS: • Synthesized 12-L
Slide 23: Multiple Form Factors: Same Proprietary TriCor 3D Technology
Multiple Form Factors: Same Proprietary TriCor 3D Technology Investor Presentation 2026 23
Slide 24: HeartBeam's On-Demand 12-Lead Patch: Disrupting the Patch Market
HeartBeam’s On-Demand 12-Lead Patch: Disrupting the Patch Market Click here to watch the video Click here to watch the video TODAY'S PATCH MARKET HEARTBEAM ON-DEMAND 12-LEAD PATCH Patch monitors are a $2B revenue market with Development of Working Prototype of existing reimbursement Patch complete D
Slide 25: HeartBeam's 12-Lead Technology Fills Key Gaps, Draws Strong Physician Demand
HeartBeam’s 12-Lead Technology Fills Key Gaps, Draws Strong Physician Demand PHYSICIANS WANT TO SWITCH PHYSICIANS WILL PRESCRIBE MORE TO 12-LEAD PATCH (MARKET ACTUALLY GROWS) PHYSICIANS THAT CURRENTLY FOR USE CASES, WHERE MDs PRESCRIBE FOR USE CASES, WHERE MDs DO PRESCRIBE PATCH MONITORS OTHER CARDI
Slide 26: HeartBeam Remote Unit: Outside of the US and Rural US
HeartBeam Remote Unit: Outside of the US and Rural US Ruggedized Phone-sized, Multi-User Device with Integrated Dry Electrodes and Built-In Communication Module • Smartphone-sized form factor • No phone required • Built-in two-way communication with AI cloud • Built-in display • Full voice-controlle
Slide 27: HeartBeam's Groundbreaking Technology is Backed by a Growing Body of Evidence
HeartBeam’s Groundbreaking Technology is Backed by a Growing Body of Evidence Technology Arrhythmia Heart Attack Proof of Concept Studies with Fundamentals of HeartBeam Pilot: Equivalence to 12-Lead ECG HeartBeam’s 3-Lead Configuration: technology Pivotal: Equivalence to 12-Lead ECG • Equivalence to
Slide 28: Financials
Financials Investor Presentation 2026 28
Slide 29: Balance Sheet Strengthened; Runway Extended
Balance Sheet Strengthened; Runway Extended • Cash and restricted cash of $8.8 million at June 30, 2026, up from $4.4 million at year-end 2025 • Reflects $11.5 million of gross proceeds from the April 2026 underwritten public offering • Round led by first commercial customer, ClearCardio; alongside
Slide 30: Financial Discipline Aligned to Achieving Milestones
Financial Discipline Aligned to Achieving Milestones Net operating cash outflow of $3.3M in Q2 YEAR-OVER-YEAR QUARTERLY CHANGE QUARTER-OVER-QUARTER CHANGE 2026, down 7% from Q1 2026. Quarter Ended June 30, Quarter Ended $ in Thousands 2026i 2025 June 30, 2026i March 31, 2026 Continued financial disc
Slide 31: Building Long-Term Value
Building Long-Term Value Investor Presentation 2026 31
Slide 32: Recent Operational Highlights
Recent Operational Highlights Consistent execution on near-term goals while advancing our long-term growth strategy ✓ Signed multiple commercial agreements across all four ➢ Established flagship commercial sites across four target target U.S. geographies: NY metro, Dallas, South Florida markets: NY,
Slide 33: Accelerating Global Adoption of Our 3D ECG Signal Platform
Accelerating Global Adoption of Our 3D ECG Signal Platform Strategic shift announced in June 2026: partner and license the platform across channels that already have distribution. Licensing the Signal Tailoring to Each WHY THE SIGNAL MATTERS: Market WHAT IT UNLOCKS: • AI needs a high-quality signal
Slide 34: Executing on a $40B Cardiac Monitoring Platform Opportunity
Executing on a $40B Cardiac Monitoring Platform Opportunity • Ability to serve 50M+ patients across multiple applications and form factors over time • Proven technology with strong IP and growing body of clinical evidence • Proprietary TriCor technology is the only technology currently cleared for a
Slide 35: Our Team
Our Team Investor Presentation 2026 35
Slide 36: Leadership Team
Leadership Team BRANISLAV VAJDIC, PHD TIM CRUICKSHANK BRYAN HUMBARGER KEN PERSEN LANCE MYERS DEBORAH CASTILLO, PHD POOJA CHATERJEE Investor Presentation 2026 36
Slide 37: Scientific Advisory Board
Scientific Advisory Board PETER FITZGERALD, MD, PHD C. MICHAEL GIBSON, MD ROBERT HARRINGTON, MD CHARLES L. BROWN III, MD TONY DAS, MD CAMPBELL ROGERS, MD NIRAJ VARMA, MD, PHD VIVEK Y. REDDY, MD Investor Presentation 2026 37
Slide 38: HeartBeam Board of Directors
HeartBeam Board of Directors RICH FERRARI BRANISLAV VAJDIC, PHD MARGA ORTIGAS-WEDEKIND WIM ELFRINK GEORGE DE URIOSTE KENNETH NELSON MICHAEL JAFF, DO Investor Presentation 2026 38
Slide 39: Redefining Cardiac Care
Company Investor Relations Redefining Tim Cruickshank CFO Chris Tyson Executive Vice President NASDAQ: BEAT Cardiac Care HeartBeam, Inc. ir@heartbeam.com MZ North America Direct: 949-491-8235 Anytime, Anywhere. www.heartbeam.com BEAT@mzgroup.us www.mzgroup.us MKT-112 v4 Investor Presentation 2026 39